Clinical Trial Update: A Phase II Clinical Study of SHR-A1904 Monotherapy in Second-Line or Later Treatment of Advanced Neuroendocrine Carcinoma [Phase 2]

View source ↗

Summary

A Phase II clinical trial of SHR-A1904 as monotherapy for second-line or later treatment of advanced neuroendocrine carcinoma, with status listed as not yet rec…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroendocrine Carcinoma

Drugs mentioned

• SHR-A1904

Snippet

Sponsor: Beijing GoBroad Hospital | Conditions: Advanced Neuroendocrine Carcinoma | Phase 2 | Status: NOT_YET_RECRUITING